Table 2.
Cost-effectiveness results for sepsis interventions
| Cost/LS (2018 USD) | Cost/LYG (2018 USD) | Cost/QALY (2018 USD) | ||||
|---|---|---|---|---|---|---|
| Intervention | n (%) | Range | n (%) | Range | n (%) | Range |
| Antibiotic therapies | 1 (20%) | $70,663/LS | 2 (40%) | $5,797/LYG to $25,565/LYG | 1 (20%) | $39,944/QALY |
| Fluid therapies | 1 (50%) | $8,211/LS | 1 (50%) | Dominant to $839/LYG | 0 (0%) | Not reported |
| Procalcitonin algorithms | 0 (0%) | Not reported | 0 (0%) | Not reported | 2 (67%) | Dominant |
| Immunoglobulin therapies | 1 (50%) | $15,738/LS | 0 (0%) | Not reported | 1 (50%) | $34,362/QALY |
| EGDT or other sepsis protocol | 3 (38%) | Dominant to $80,852/LS | 3 (38%) | $5,787/LYG to $14,981/LYG | 5 (63%) | Dominant to $21,691/QALY |
| Pathogen identification | 1 (25%) | $16,789/LS | 0 (0%) | Not reported | 2 (50%) | $2,199/QALY to Dominated |
| Other therapies | 1 (50%) | $4,029/LS | 0 (0%) | Not reported | 1 (50%) | $34,984/QALY |
| Interventions no longer in clinical practice | ||||||
| Drotecogin alfa (activated) | 3 (23%) | $79,418/LS to $233,600/LS | 10 (77%) | $2,696/LYG to $48,618/LYG | 9 (69%) | $3,901/QALY to $71,248/QALY |
| Monoclonal antibodies | 4 (57%) | $24,719/LS to $379,579/LS | 3 (43%) | $2,679/LYG to $1,830,283/LYG | 0 (0%) | Not reported |
EGDT early goal directed therapy, LS life saved, LYG life years gained, QALY quality-adjusted life year, USD United States dollar